Introduction
Mycobacterium tuberculosis is responsible for at least 2 million deaths per year worldwide and 30 million people are at risk of dying from tuberculosis (TB) in the next 10 years. 1 Due to demographic factors, socio-economic trends, neglected tuberculosis control in many countries and HIV-infection, this epidemic has been able to adopt such proportions. Efforts to stop this frightening trend are hampered by the lack of financial resources in developing countries, the appearance of multi-drug resistant strains of M. tuberculosis and bad therapy compliance. As a current strategy in the battle against TB, Directly Observed Treatment Short-course (DOTS)
is preferred. In DOTS, TB patients are subjected to standardized treatment regimens (generally consisting of combinations of the most powerful anti-TB drugs), which last 6-8 months under direct observation of drug intake. As a consequence, the duration of illness, the risk of death and the appearance of resistant strains are reduced. For those that are or will be infected with the multi-drug-resistant bacteria or that develop resistance after a previous drug treatment (50-80% of previously treated cases), however, more effective drugs acting on novel targets are eagerly awaited.
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Thymidine monophosphate kinase (TMPK) catalyzes the conversion of dTMP to dTDP. This enzyme is ubiquitous in all living organisms. It lies at the junction of the de novo and salvage pathways for thymidine triphosphate (dTTP) synthesis. These enzymes are well characterized, both at biochemical 3 and structural 4 levels. Li de la Sierra et al. recently determined the structure of M. tuberculosis TMPK (TMPKmt) using X-ray diffraction. 5 Because its crucial role in thymidine metabolism and in view of its low (22%) sequence identity with the human isozyme (TMPKh), it represents an attractive target for blocking mycobacterial DNA synthesis. The main interactions between dTMP and the enzyme are depicted in Figure 1 . The most important catalytic regions are:
-the P-loop (amino acid residues 617), which binds and positions the -and -phosphoryl groups of the phosphate donor (ATP); it is unique among all known TMPK sequences in that it does not have an arginine at the position where it is found in the yeast and human enzymes; instead, it possesses a distant arginine residue four amino acids further;
-the DRY/H-motif (residues 9496), which acts as a clip that favorably orients the phosphate donor and acceptor;
-the LID-region (residues 144154) that leans over the phosphoryl donor, when dTMP binds the enzyme; it is very similar to E. coli TMPK having three arginines.
Moreover, 3'-azido-3'-deoxythymidine monophosphate (AZTMP) was identified as a competitive inhibitor of TMPKmt with a K i of 10 M. 3d TMPKmt represents the first reported TMPK that does not phosphorylate AZTMP, a feature that could be exploited in the search for other selective inhibitors of TMPKmt. Lavie et al. 4a postulated that, in yeast TMPK, the azido group interacts via its terminal nitrogen with the side-chain carboxyl of Asp9, resulting in a Ploop displacement. Thus, Arg15 binds ATP less efficiently, slowing down catalysis. A similar mechanism may account for the lack of phosphorylation of AZTMP by TMPKmt. Li de la Sierra et al. 5 suggested that the azido group carries the magnesium ion into the active site of TMPKmt (responsible for positioning one oxygen of the phosphate and Asp9), thereby abolishing catalysis. Despite the uncertainty of the mechanism, it should be interesting to explore changes at position 3'of the dTMP-scaffold for finding more potent inhibitors of TMPKmt. The X-ray structure of TMPK complexed with dTMP reveals that relatively bulky substituents at the 3'-position could be accommodated. 5 Therefore, we decided to synthesize a series of 3'-C-branched-chain nucleotides, namely the 3'-C-azidomethyl, 3'-C-aminomethyl, 3'-C-fluoromethyl, and 3'-C-hydroxymethyl derivatives of dTMP (3-6). To delineate the most appropriate length of the spacer between the 3'-carbon and the introduced functionality, also 3'-deoxy-3'-hydroxyethylthymidine (15) was investigated for its affinity for TMPKmt.
We have already reported that a ribo analogue exhibits a higher affinity for TMPKmt than its corresponding 2'-deoxy analogue, i.e. the ribo analogue of 3'-amino-3'-deoxy-5'-Ophosphorylthymidine (2) with a K i of 27 M versus 235 M for 1. 6 In order to gain detailed insight in the postulated steric hindrance caused by Tyr103 at the 2'-position, the ribo analogues of the azido and amino compounds were also synthesized (7) (8) . The nonphosphorylated analogues 9-14 of the above-mentioned compounds were included in this report as well.
Results and Discussion

Chemistry
Although an efficient synthetic route for the synthesis of 3'-C-branched-chain 2',3'-deoxy substituted thymidine has been established, 7 we developed a route that gives access to both 2'-deoxy and ribo analogues and allows easier conversion to the corresponding monophosphates.
The synthesis of the parent 3'-C-branched-chain substituted nucleosides 9-14 was described by Lin et al. 8 In this procedure, all 3'-C-modifications are introduced on the sugar moiety before coupling with thymine. In our approach, the 3'-C-modifications are effected following sugar-base coupling, which allows synthesizing all derivatives from a unique key intermediate. This approach requires a judicious choice of 5'-and 6'-O-protective groups, which must be stable under various reaction conditions and be chemoselectively removed to permit conversion of the key compound to the 3'-hydroxymethylnucleotide, on one hand and to the 3'-azidomethyl-, 3'-aminomethyl-and 3'-fluoromethyl-derivatives, on the other hand. and O-benzyl group of 24 by catalytic hydrogenolysis, followed by 5'-O-phosphorylation and removal of the p-anisyl group, gave the desired 2',3'-dideoxy-3'-C-hydroxymethylthymidine-5'-O-monophosphate (6) (Scheme 4). To obtain the corresponding free nucleoside 12, 25 was treated with ceric ammonium nitrate. Besides the removal of the 6'-O-anisyl group, oxidation by reductive debenzylation, afforded the desired 2',3'-dideoxy-3'-fluoromethylnucleoside 11.
Phosphorylation of the 5'-hydroxyl group led to the corresponding nucleotide 5 (Scheme 4).
Mesylation of 28 followed by treatment with NaN 3 afforded azide 30 in 79% yield (2 steps) (Scheme 5). Debenzylation (BCl 3 in CH 2 Cl 2 ), followed by 5'-phosphorylation, furnished 3'-C-azidomethyl nucleotide 3. Reduction of the azido group in 3 with Ph 3 P and NH 4 OH in pyridine led to the 3'-CH 2 NH 2 derivative 4. Likewise 9 was converted to 10.
The synthesis of the 3'-C-aminomethyl and 3'-C-azidomethyl ribo analogues from 23 was performed in a similar way as for the 2'-deoxy analogues. After selective removal of the panisyl group of 23, the 6'-azido moiety was introduced via mesylation and treatment with NaN 3 to yield nucleoside 13 after deprotection. Phosphorylation of 13 led to analogue 7 and subsequent reduction of the 6'-azido group afforded analogue 8. Similarly, reduction of the azido group of 13 afforded 14.
Compound 15 was obtained according to reported procedures with slight modifications (Scheme 6). An allyl group was introduced at the 3'-position of 5'-silylated thymidine by a free-radical coupling described by C.K. Chu 14 to give nucleoside 33. Aldehyde 34 was obtained from 33 by a two-step one-pot procedure involving cis-hydroxylation with osmium tetraoxide in the presence of 4-methylmorpholine N-oxide and sodium periodate cleavage of the diol. 15 Reduction of 34 with sodium borohydride in aqueous ethanol, followed by 5'-desilylation of the alcohol 35, afforded the free nucleoside 15 in 24% yield from 33.
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Binding Assay
All compounds were tested as described in the experimental section 17 and are presented in Table 1 . Clearly, 2'-deoxy nucleotides 3-6 are potent inhibitors of TMPKmt. The 3'-CH 2 NH 2 nucleotide 4, its 3'-CH 2 N 3 precursor 3 and the 3'-CH 2 F nucleotide 5 exhibit the highest affinities within this series with K i values of 10.5 M, 12 M and 15 M, respectively. A modeling experiment (in GOLD) showed that 4 adopts a 2'-exo-3'-endo conformation (dTMP, in contrast, is in the crystal in the 2'-endo-3'-exo conformation). Consequently, the amino group occupies the same space as the 3'-hydroxylgroup of dTMP, hence it is in an appropriate position to interact with Asp9 ( Figure 2 ).
These results indicate that TMPKmt can accommodate sterically more demanding substituents at the 3'-position. Since 5 binds the enzyme as efficiently as 3 and 4, ionic interaction with Asp9 seems not a prerequisite for effective affinity. Interestingly, deletion of the phosphate moiety typically results in a modest (at most 6-fold) affinity loss, while this effect is negligible in the case of the 3'-CH 2 OH substituent. The largest discrepancy between the K i values of the free and phosphorylated forms is found for the 3'-CH 2 NH 2 couple. The positively charged ammonium ion may well interact with the negatively charged phosphate moiety, thereby forcing the nucleotide in a favorable conformation for interaction with
TMPKmt. In the absence of the phosphoryl group, this conformation is no longer preferred and the conformational mobility of the 3'-CH 2 NH 2 may account for the loss of affinity.
Because nucleotide 2 has a much higher affinity than the corresponding 2'-deoxyribo analogue 1, compound 8 was expected to be active. However, introduction of a methylene spacer between the NH 2 -group and C-3' of 2, leads to 8 with a 30-fold lower affinity than the deoxyribo analogue 4. The affinities of the other ribo analogues were weak, the smallest decrease (6-fold) in affinity upon introduction of the 2'-hydroxyl being found for 14.
Apparently, the presence of Tyr103 close to the 2'-position impedes favorable binding characteristics of these ribo analogues. Thus, compound 2 is the only ribo analogue with a higher affinity than its deoxy counterpart.
In order to probe the influence of the arm length at position 3', 15 was synthesized. Its K i value was 5.8 and 3.8 times higher than that of dT (n= 0) and 12 (n = 1), respectively.
The selectivity of all target compounds for TMPKmt versus TMPKh was evaluated. All are inhibitors of TMPKh except the 3'-hydroxymethylnucleotide 6, which behaves as a weak substrate. Most nucleotides (3, 5, 6 and 8) show affinities for TMPKh that lie in the same order of magnitude as those for TMPKmt. The non-phosphorylated 3'-C-branched-chain nucleosides 9, 11 and 12, on the other hand exhibit very low affinities for TMPKh, which results in selectivity indexes between 10 and 26. Somehow a 3'-CH 2 N 3 functionality combined with a 2'-hydroxyl seems to introduce a TMPKmt versus TMPKh selectivity in these 3'-Cbranched-chain analogues, whereas an opposite tendency is observed upon reduction of the 3'-CH 2 N 3 group. To conclude, nucleosides 9, 11 and 12 emerge as the inhibitors that combine a low K i value with a favourable SI ratio and are therefore put forward as promising leads for further research.
Conclusions
In the search for more potent drugs to treat tuberculosis, the discovery of new leads with a novel mechanism of action is of utmost importance. and TMPKh (will be described elsewhere by Pochet et al.). TMPKmt and TMPKh activities were determined using the coupled spectrophotometric assay described by Blondin et al. 17 at 334 nm in an Eppendorf ECOM 6122 photometer. The reaction medium (0.5 ml final volume) contained 50 mM Tris-HCl pH 7.4, 50 mM KCl, 2 mM MgCl 2 , 0.2 mM NADH, 1 mM phosphoenol pyruvate and 2 units each of lactate dehydrogenase, pyruvate kinase and nucleoside diphosphate kinase. The concentrations of ATP and dTMP were kept constant at 0.5 mM and 0.05 mM respectively, whereas the concentrations of analogues varied between 0.01 and 4 mM.
(2) Modeling
The X-ray structure of TMPKmt published by de la Sierra et al. 5 (pdb entry 1G3U) was used in all docking experiments. Water molecules and sulphate counter ions were removed. The Mg 2+ was considered as being part of the enzyme. Explicit hydrogen atoms were added to the enzyme and inhibitor structures using Reduce. 18 PDB files were then converted to mol2 files using Babel. 19 The position of atom C1' in the dTMP ligand in the pdb file 1G3U was used as the center of a 20 Å docking sphere. Default settings were used in Gold for all dockings. 20, 21 The structures in the top 25 of the docking scores were retained for visual inspection and analysis. Figures 1 and 2 were generated using Molscript. Anhydrous solvents were obtained as follows: THF was distilled from sodium/benzophenone; pyridine was refluxed overnight over potassium hydroxide and distilled; dichloromethane, dichloroethane and toluene were stored over calcium hydride, refluxed, and distilled; DMF was stored over Linde 4 Å molecular sieves, followed by distillation under reduced pressure. 
3-[(p-Anisyloxy)methyl]-5-O-benzyl-3-deoxy-1,2-O-(isopropylidene)--D-ribofuranose (21).
1-3-[(p-Anisyloxy)methyl]-5-O-benzyl-3-deoxy--D-ribofuranosylthymine (23).
Thymine (225 mg, 1.78 mmol) was suspended in hexamethyldisilazane (20 mL, 95 mmol) containing trimethylsilylchloride (0.16 mL, 1.26 mmol) and pyridine (1.6 mL). The mixture was heated at reflux overnight. The reaction mixture was evaporated and coevaporated with toluene. The resulting residue and 22 (720 mg, 1.62 mmol) were dissolved in dry 1,2-dichloroethane (12 ml) and trimethylsilyl triflate (0.34 ml, 1.88 mmol) was added dropwise. 
1-3-[(p-
1-(2,3-Dideoxy-3-hydroxymethyl--D-erythro-pentofuranosyl)-5-hydroxymethylthymine (27)
.
General procedure for the selective phosphorylation of the 5'-hydroxylgroup.
To a cooled (0 °C) solution of the nucleoside (0.42 mmol) in trimethyl phosphate (10 mL/mmol), POCl 3 (6.5 eq) was added dropwise and the mixture was stirred for 5 h at 0 °C and for 30 min at room temperature, after which it was poured into crushed ice-water (10 mL), neutralized with concentrated NH 4 OH and evaporated to dryness. The resulting residue was purified by column chromatography (iPrOH NH 4 OHH 2 O, 77.5:15:2.560:30:5).
Further purification of the white powder by HPLC (C-18, CH 3 CNMeOH0.05% HCOOH in H 2 O 45:45:10, 3 mL/min) and lyophilisation of the appropriate fractions, provided the nucleotide as a white powder.
1-3-[(p-Anisyloxy)methyl]-2,3-dideoxy-5-O-phosphoryl-D-erythropentofuranosylthymine (26)
. 25 was phosphorylated as described in the general procedure and nucleotide 26 isolated in 52% yield. 
1-[2,3-Dideoxy-3-(hydroxymethyl)-5-O-phosphoryl--D-erythro-pentofuranosyl]thymine (6).
1-[5-O-Benzyl-2,3-dideoxy-3-(hydroxymethyl)--D-erythro-pentofuranosyl]thymine (28).
To 
1-[2,3-Dideoxy-3-(hydroxymethyl)--D-erythro-pentofuranosyl]thymine (12).
Hydrogenation of 28 (62.0 mg, 0.179 mmol) was accomplished at atmospheric pressure of H 2 at room temperature for 45 min using 10% Pd/C (50 mg) in MeOH (5 mL 
1-[5-O-Benzyl-2,3-dideoxy-3-(fluoromethyl)--D-erythro-pentofuranosyl]thymine (29).
DAST (0.280 mL, 2.12 mmol) was dissolved in CH 2 Cl 2 (5 mL) and pyridine (0.36 mL) at 0 °C under nitrogen. Nucleoside 28 (619 mg, 1.79 mmol) was added in several portions and the solution was allowed to warm to room temperature. After 7 h, the solvent was removed under vacuum to give a syrup which was purified by column chromatography (CH 2 Cl 2 MeOH, 
1-[3-(Azidomethyl)-5-O-benzyl-2,3-dideoxy--D-erythro-pentofuranosylthymine (30).
Methanesulfonyl chloride (0.180 mL, 2.33 mmol) was added to a solution of compound 28
(306 mg, 0.883 mmol) in pyridine (3 mL) at 0 °C. The reaction mixture was stirred at 0 °C during 1 h. Then it was diluted with CH 2 Cl 2 (50 mL), washed with saturated aqueous NaHCO 3 (50 mL) and dried over anhydrous 
1-[3-(Aminomethyl)-2,3-dideoxy--D-erythro-pentofuranosyl]thymine (10). Compound 9
(169 mg, 0.60 mmol) and triphenylphosphine (252 mg, 0.96 mmol) were dissolved in pyridine (7 mL) and stirred at room temperature. After 1h, concentrated NH 4 OH (6 mL) was added and the solution was allowed to stir for an additional 2h. Pyridine was removed under reduced pressure, water (8 mL) was added and the unreacted triphenylphosphine and triphenylphosphine oxide were removed by filtration. The filtrate was extracted with toluene and the water layer was evaporated under reduced pressure to give a syrup. 
